cluding the use of matched placebo and remote central rat-
ers, blinded to treatment assignment and duration of treat-
ment, for the primary outcome assessment. Given the low
incidence of adverse events with lumateperone and place-
bolike changes in body weight, cardiometabolic, and extrapy-
ramidal measures, there was little possibility of functional un-
blinding. That more patients randomized to placebo
discontinued owing to inefficacy is expected because they did
not receive clinical benefit of active treatment.

Christoph U. Correll, MD
Hassan D. Lakkis, PhD
Kimberly E. Vanover, PhD

Author Affiliations: Department of Psychiatry and Molecular Medicine, Zucker
School of Medicine at Hofstra/Northwell, Hempstead, New York (Correll); Department of Psychiatry, Zucker Hillside Hospital, Glen Oaks, New York (Correll); Department of Child and Adolescent Psychiatry, Charité
Universitätsmedizin Berlin, Berlin, Germany (Correll); Intra-Cellular Therapies Inc, New York, New York (Lakkis, Vanover).

Corresponding Author: Kimberly E. Vanover, PhD, Intra-Cellular Therapies,
Alexandria Center for Life Science, 430 E 29th St, Ste 900, New York, NY 10016
(kvanover@itci-inc.com).

Published Online: April 22, 2020. doi:10.1001/jamapsychiatry.2020.0613

Conflict of Interest Disclosures: Dr Correll reported receiving personal fees
from Intra-Cellular Therapies during the conduct of the study and grants from
Janssen and Takeda and personal fees from Acadia, Allergan, Angelini, Assome, Gedeon Richter, Gerson Lehrman Group, Intra-Cellular
Therapies, Janssen/J&J, LB Pharma, Lundbeck, MedAvante-ProPhase,
Medscape, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Sumitomo
Dainippon, Sunovion, Supernus, UpToDate, Takeda, and Teva outside the
submitted work. Drs Lakkis and Vanover reported receiving personal fees from
Intra-Cellular Therapies during the conduct and/or analyses phase of the study.

Funding/Support: The original study was supported by Intra-Cellular Therapies Inc.

Role of the Funder/Sponsor: Intra-Cellular Therapies Inc sponsored the design
and conduct of the study; collection, management, analysis, and interpretation
of the data; preparation, review, or approval of the manuscript; and decision to
submit the manuscript for publication.

for treatment of schizophrenia: a randomized clinical trial. JAMA Psychiatry.
Published online January 8, 2020. doi:10.1001/jamapsychiatry.2019.4379

and tolerability of 32 oral antipsychotics for the acute treatment of adults
with multi-episode schizophrenia: a systematic review and network meta-analysis.

antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian

4. Lieberman JA, Davis RE, Correll CU, et al. ITI-007 for the treatment of
schizophrenia: a 4-week randomized, double-blind, controlled trial. Biol Psychiatry.
2016;79(12):952-961. doi:10.1016/j.biopsych.2015.08.026


CORRECTION

Update to Open Access Status: In the Original Investigation titled “Association of
Magnetoencephalographically Measured High-Frequency Oscillations in Visual Cor-
xus With Circuit Dysfunctions in Local and Large-scale Networks During Emerging
Psychosis,” published online March 25, 2020, the authors updated the status of the
article so that it is now Open Access. This article has been corrected online.

graphically measured high-frequency oscillations in visual cortex with circuit
dysfunctions in local and large-scale networks during emerging psychosis
[published online March 25, 2020]. JAMA Psychiatry. doi:10.1001/
jamapsychiatry.2020.0284